Diabetic cardiomyopathy

Clinical Science

Volumn 116, Issue 10, 2009, Pages 741-760

  Asghar, Omar ^a   Al Sunni, Ahmed ^b   Khavandi, Kaivan ^b   Khavandi, Ali ^c   Withers, Sarah ^b   Greenstein, Adam ^b   Heagerty, Anthony M ^b   Malik, Rayaz A ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Diabetic cardiomyopathy; Heart failure; Hyperglycaemia; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; FATTY ACID; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; METALLOTHIONEIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; ORAL ANTIDIABETIC AGENT; PERHEXILINE; PIOGLITAZONE; PROTEIN KINASE C; RANOLAZINE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TEMPOL; TRIMETAZIDINE; UNINDEXED DRUG; VASCULOTROPIN;

BLOOD PRESSURE REGULATION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG SAFETY; ELECTROCARDIOGRAM; ENZYME INHIBITION; EXPERIMENTAL MODEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN TREATMENT; KALLIKREIN KININ SYSTEM; KIDNEY FAILURE; METABOLIC SYNDROME X; MICROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC DYSFUNCTION;

BIOLOGICAL MARKERS; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART FAILURE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MICROCIRCULATION; OXIDATIVE STRESS; RISK FACTORS;

EID: 67649285971     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080500     Document Type: Review

References (209)

1. Leyden, E. (1881) Asthma and diabetes mellitus. Zeutschr. Klin. Med. 3, 358-364
2. Mayer, J. (1888) Ueber den zusammenhang des diabetes mellitus miterkrankungen des herzens. Zeutschr. Klin. Med. 14, 212-239
3. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A.W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602
4. Hayat, S. A., Patel, B., Khattar, R. S. and Malik, R. A. (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. 107, 539-557
5. Thrainsdottir, I. S., Aspelund, T., Thorgeirsson, G., Gudnason, V., Hardarson, T., Malmberg, K., Sigurdsson, G. and Ryden, L. (2005) The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28, 612-616 (Pubitemid 40315321)
6. Bertoni, A. G., Hundley, W. G., Massing, M. W., Bonds, D. E., Burke, G. L. and Goff, Jr, D. C. (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27, 699-703
7. Reis, S. E., Holubkov, R., Edmundowicz, D., McNamara, D. M., Zell, K. A., Detre, K. M. and Feldman, A. M. (1997) Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J. Am. Coll. Cardiol. 30, 733-738
8. Cohen-Solal, A., Beauvais, F. and Logeart, D. (2008) Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J. Card. Failure 14, 615-625
9. Amato, L., Paolisso, G., Cacciatore, F., Ferrara, N., Ferrara, P., Canonico, S., Varricchio, M. and Rengo, F. (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 23, 213-218
10. Berry, C., Brett, M., Stevenson, K., McMurray, J. J. and Norrie, J. (2008) Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart 94, 296-304 (Pubitemid 351303420)
11. Mak, K. H., Moliterno, D. J., Granger, C. B., Miller, D. P., White, H. D., Wilcox, R. G., Califf, R. M. and Topol, E. J. (1997) Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J. Am. Coll. Cardiol. 30, 171-179
12. Kannel, W. B., Hjortland, M. and Castelli, W. P. (1974) Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29-34
13. Bertoni, A. G., Tsai, A., Kasper, E. K. and Brancati, F. L. (2003) Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26, 2791-2795 (Pubitemid 37205548)
14. Gottdiener, J. S., Arnold, A. M., Aurigemma, G. P., Polak, J. F., Tracy, R. P., Kitzman, D.W., Gardin, J. M., Rutledge, J. E. and Boineau, R. C. (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 35, 1628-1637
15. Devereux, R. B., Roman, M. J., Paranicas, M., O'Grady, M. J., Lee, E. T.,Welty, T. K., Fabsitz, R. R., Robbins, D., Rhoades, E. R. and Howard, B. V. (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101, 2271-2276 (Pubitemid 30317129)
16. Bertoni, A. G., Goff, Jr, D. C., D'Agostino, Jr, R. B., Liu, K., Hundley, W. G., Lima, J. A., Polak, J. F., Saad, M. F., Szklo, M., Tracy, R. P. and Siscovick, D. S. (2006) Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 29, 588-594 (Pubitemid 44115359)
17. Nichols, G. A., Hillier, T. A., Erbey, J. R. and Brown, J. B. (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24, 1614-1619 (Pubitemid 33716458)
18. Aronow, W. S. and Ahn, C. (1999) Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest 115, 867-868 (Pubitemid 29129974)
19. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C. and Holman, R. R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321, 405-412
20. Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S. and Selby, J. V. (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103, 2668-2673 (Pubitemid 32538780)
21. Cheung, N., Wang, J. J., Rogers, S. L., Brancati, F., Klein, R., Sharrett, A. R. and Wong, T. Y. (2008) Diabetic retinopathy and risk of heart failure. J. Am. Coll. Cardiol. 51, 1573-1578
22. Cheung, N., Bluemke, D. A., Klein, R., Sharrett, A. R., Islam, F. M., Cotch, M. F., Klein, B. E., Criqui, M. H. and Wong, T. Y. (2007) Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J. Am. Coll. Cardiol. 50, 48-55
23. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302
24. Komajda, M., Wimart, M. C. and Thibout, E. (1994) The ATLAS study (Assessment of Treatment with Lisinopril and Survival); justification and objectives. Arch. Mal. Coeur Vaiss 87, 45-50
25. Cohn, J. N., Archibald, D. G., Ziesche, S., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H. et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314, 1547-1552
26. McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R. et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100, 1056-1064 (Pubitemid 29416231)
27. Ingelsson, E., Arnlov, J., Lind, L. and Sundstrom, J. (2006) Metabolic syndrome and risk for heart failure in middle-aged men. Heart 92, 1409-1413 (Pubitemid 44578829)
28. Ingelsson, E., Sundstrom, J., Arnlov, J., Zethelius, B. and Lind, L. (2005) Insulin resistance and risk of congestive heart failure. JAMA, J. Am. Med. Assoc. 294, 334-341 (Pubitemid 41043777)
29. Bahrami, H., Bluemke, D. A., Kronmal, R., Bertoni, A. G., Lloyd-Jones, D. M., Shahar, E., Szklo, M. and Lima, J. A. (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J. Am. Coll. Cardiol. 51, 1775-1783
30. Hassan, S. A., Deswal, A., Bozkurt, B., Aguilar, D., Mann, D. L. and Pritchett, A. M. (2008) The metabolic syndrome and mortality in an ethnically diverse heart failure population. J. Card. Failure 14, 590-595
31. Andersen, N. H., Poulsen, S. H., Poulsen, P. L., Knudsen, S. T., Helleberg, K., Hansen, K. W., Dinesen, D. S., Eiskjaer, H., Flyvbjerg, A. and Mogensen, C. E. (2006) Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin. Sci. 111, 53-59
32. Fang, Z. Y., Schull-Meade, R., Downey, M., Prins, J. and Marwick, T. H. (2005) Determinants of subclinical diabetic heart disease. Diabetologia 48, 394-402 (Pubitemid 40543314)
33. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. and Neil, H. A. (2008) 10-Year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589
34. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D. et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572
35. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, Jr, D. C., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail-Beigi, F., Grimm, Jr, R. H. et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559
36. Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. and Matthews, D. R. (2008) Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med. 359, 1565-1576
37. Levy, D., Garrison, R. J., Savage, D. D., Kannel,W. B. and Castelli, W. P. (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561-1566
38. Yotsukura, M., Suzuki, J., Yamaguchi, T., Sasaki, K., Koide, Y., Mizuno, H., Yoshino, H. and Ishikawa, K. (1998) Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction. J. Electrocardiol. 31, 91-99 (Pubitemid 28193837)
39. Quinones, M. A., Greenberg, B. H., Kopelen, H. A., Koilpillai, C., Limacher, M. C., Shindler, D. M., Shelton, B. J. and Weiner, D. H. (2000) Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. 35, 1237-1244
40. Boner, G., Cooper, M. E., McCarroll, K., Brenner, B. M., de Zeeuw, D., Kowey, P. R., Shahinfar, S., Dickson, T., Crow, R. S. and Parving, H. H. (2005) Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48, 1980-1987 (Pubitemid 41416906)
41. Lopez-Gomez, J. M., Verde, E. and Perez-Garcia, R. (1998) Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int. Suppl. 68, S92-S98
42. Eguchi, K., Ishikawa, J., Hoshide, S., Ishikawa, S., Pickering, T. G., Schwartz, J. E., Homma, S., Shimada, K. and Kario, K. (2007) Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. Am. Heart J. 154, 79.e9-79.e15
43. de Simone, G., Gottdiener, J. S., Chinali, M. and Maurer, M. S. (2008) Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur. Heart J. 29, 741-747
44. Pierdomenico, S. D., Lapenna, D. and Cuccurullo, F. (2008) Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am. J. Hypertens. 21, 464-470
45. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., Remuzzi, G., Snapinn, S. M., Zhang, Z. and Shahinfar, S. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869
46. Danielsen, R., Nordrehaug, J. E., Lien, E. and Vik-Mo, H. (1987) Subclinical left ventricular abnormalities in young subjects with long-term type 1 diabetes mellitus detected by digitized M-mode echocardiography. Am. J. Cardiol. 60, 143-146
47. Ozasa, N., Furukawa, Y., Morimoto, T., Tadamura, E., Kita, T. and Kimura, T. (2008) Relation among left ventricular mass, insulin resistance, and hemodynamic parameters in type 2 diabetes. Hypertens. Res. 31, 425-432
48. Sundstrom, J., Arnlov, J., Stolare, K. and Lind, L. (2008) Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study. Heart 94, 874-878 (Pubitemid 351914697)
49. Zile, M. R., Baicu, C. F. and Gaasch, W. H. (2004) Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N. Engl. J. Med. 350, 1953-1959
50. van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J., Schalkwijk, C. G., Bronzwaer, J. G., Diamant, M. et al. (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51 (Pubitemid 350291180)
51. Karamitsos, T. D., Karvounis, H. I., Dalamanga, E. G., Papadopoulos, C. E., Didangellos, T. P., Karamitsos, D. T., Parharidis, G. E. and Louridas, G. E. (2007) Early diastolic impairment of diabetic heart: the significance of right ventricle. Int. J. Cardiol. 114, 218-223
52. Zabalgoitia, M., Ismaeil, M. F., Anderson, L. and Maklady, F. A. (2001) Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am. J. Cardiol. 87, 320-323
53. Boyer, J. K., Thanigaraj, S., Schechtman, K. B. and Perez, J. E. (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol. 93, 870-875
54. Ha, J. W., Lee, H. C., Kang, E. S., Ahn, C. M., Kim, J. M., Ahn, J. A., Lee, S. W., Choi, E. Y., Rim, S. J., Oh, J. K. and Chung, N. (2007) Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography. Heart 93, 1571-1576 (Pubitemid 350205552)
55. Svealv, B. G., Olofsson, E. L. and Andersson, B. (2008) Ventricular long-axis function is of major importance for long-term survival in patients with heart failure. Heart 94, 284-289 (Pubitemid 351303416)
56. Fang, Z. Y., Schull-Meade, R., Leano, R., Mottram, P. M., Prins, J. B. and Marwick, T. H. (2005) Screening for heart disease in diabetic subjects. Am. Heart J. 149, 349-354
57. Fang, Z. Y., Yuda, S., Anderson, V., Short, L., Case, C. and Marwick, T. H. (2003) Echocardiographic detection of early diabetic myocardial disease. J. Am. Coll. Cardiol. 41, 611-617
58. Yu, C. M., Lin, H., Yang, H., Kong, S. L., Zhang, Q. and Lee, S. W. (2002) Progression of systolic abnormalities in patients with 'isolated' diastolic heart failure and diastolic dysfunction. Circulation 105, 1195-1201
59. Maciver, D. H. and Townsend, M. (2008) A novel mechanism of heart failure with normal ejection fraction. Heart 94, 446-449
60. Aurigemma, G. P., Zile, M. R. and Gaasch, W. H. (2006) Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 113, 296-304 (Pubitemid 43754388)
61. Fang, Z. Y., Leano, R. and Marwick, T. H. (2004) Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin. Sci. 106, 53-60
62. Zornoff, L. A., Skali, H., Pfeffer, M. A., St John Sutton, M., Rouleau, J. L., Lamas, G. A., Plappert, T., Rouleau, J. R., Moyé, L. A., Lewis, S. J. et al. (2002) Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J. Am. Coll. Cardiol. 39, 1450-1455
63. Zile, M. R., Gaasch,W. H., Carroll, J. D., Feldman, M. D., Aurigemma, G. P., Schaer, G. L., Ghali, J. K. and Liebson, P. R. (2001) Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104, 779-782
64. Galderisi, M. (2006) Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J. Am. Coll. Cardiol. 48, 1548-1551
65. Edvardsen, T., Gerber, B. L., Garot, J., Bluemke, D. A., Lima, J. A. and Smiseth, O. A. (2002) Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 106, 50-56 (Pubitemid 34747441)
66. Gotte, M. J., van Rossum, A. C., Twisk, J.W. R., Kuijer, J. P. A., Marcus, J. T. and Visser, C. A. (2001) Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J. Am. Coll. Cardiol. 37, 808-817
67. Chuang, M. L., Beaudin, R. A., Riley, M. F., Mooney, M. G., Mannin, W. J., Douglas, P. S. and Hibberd, M. G. (2000) Three-dimensional echocardiographic measurement of left ventricular mass: comparison with magnetic resonance imaging and two-dimensional echocardiographic determinations in man. Int. J. Cardiac Imaging 16, 347-357 (Pubitemid 32058500)
68. Maisel, A. S., McCord, J., Nowak, R. M., Hollander, J. E., Wu, A. H.,Duc, P., Omland, T., Storrow,A. B., Krishnaswamy, P., Abraham, W. T. et al. (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J. Am. Coll. Cardiol. 41, 2010-2017
69. Shen, X. and Bornfeldt, K. E. (2007) Mouse models for studies of cardiovascular complications of type 1 diabetes. Ann. N. Y. Acad. Sci. 1103, 202-217
70. Retnakaran, R. and Zinman, B. (2008) Type 1 diabetes, hyperglycaemia, and the heart. Lancet 371, 1790-1799 (Pubitemid 351697955)
71. 2+ cycling proteins, NADPH oxidase, poly(ADP-ribose) polymerase and myosin heavy chain isozyme. Free Radical Biol. Med. 40, 1419-1429
72. Liang, Q., Carlson, E. C., Donthi, R. V., Kralik, P. M., Shen, X. and Epstein, P. N. (2002) Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51, 174-181 (Pubitemid 34517995)
73. Cai, L., Wang, Y., Zhou, G., Chen, T., Song, Y., Li, X. and Kang, Y. J. (2006) Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 48, 1688-1697
74. Ye, G., Metreveli, N. S., Donthi, R. V., Xia, S., Xu, M., Carlson, E. C. and Epstein, P. N. (2004) Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53, 1336-1343 (Pubitemid 38569021)
75. Seddon, M., Looi, Y. H. and Shah, A. M. (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93, 903-907 (Pubitemid 47122034)
76. Gao, W. D., Liu, Y. and Marban, E. (1996) Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 94, 2597-2604
77. Li, J.-M., Gall, N. P., Grieve, D. J., Chen, M. and Shah, A. M. (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477-484
78. 2+ cycling proteins, NADPH oxidase, poly(ADP-ribose) polymerase and myosin heavy chain isozyme. Free Radical Biol. Med. 40, 1419-1429
79. Ritchie, R. H., Quinn, J. M., Cao, A. H., Drummond, G. R., Kaye, D. M., Favaloro, J. M., Proietto, J. and Delbridge, L. M. (2007) The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J. Mol. Cell. Cardiol. 42, 1119-1128
80. Tesfamariam, B., Brown, M. L. and Cohen, R. A. (1991) Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 87, 1643-1648
81. Duncan, E. R., Walker, S. J., Ezzat, V. A., Wheatcroft, S. B., Li, J. M., Shah, A. M. and Kearney, M. T. (2007) Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am. J. Physiol. Endocrinol. Metab. 293, E1311-E1319
82. Hornig, B., Arakawa, N., Kohler, C. and Drexler, H. (1998) Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97, 363-368 (Pubitemid 28074337)
83. MacCarthy, P. A., Grieve, D. J., Li, J. M., Dunster, C., Kelly, F. J. and Shah, A. M. (2001) Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104, 2967-2974 (Pubitemid 33139111)
84. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J. and Sleight, P. (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 154-160
85. Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z., Szabó, C. and Brownlee, M. (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112, 1049-1057
86. Reference deleted
87. Szabo, C. (2002) PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect. 15, 197-205 (Pubitemid 34665689)
88. Minchenko, A. G., Stevens, M. J., White, L., Abatan, O. I., Komjáti, K., Pacher, P., Szabó, C. and Obrosova, I. G. (2003) Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 17, 1514-1516
89. Chiu, J., Farhangkhoee, H., Xu, B. Y., Chen, S., George, B. and Chakrabarti, S. (2008) PARP mediates structural alterations in diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 45, 385-393
90. Yang, Z., Zingarelli, B. and Szabo, C. (2000) Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13, 60-66
91. Soriano, F. G., Pacher, P., Mabley, J., Liaudet, L. and Szabo, C. (2001) Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89, 684-691
92. 2+-sensitive isoforms in the failing human heart. Circulation 99, 384-391
93. Way, K. J., Isshiki, K., Suzuma, K., Yokota, T., Zvagelsky, D., Schoen, F. J., Sandusky, G. E., Pechous, P. A., Vlahos, C. J., Wakasaki, H. and King, G. L. (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C β2 activation and diabetes. Diabetes 51, 2709-2718 (Pubitemid 34970923)
94. Koya, D. and King, G. L. (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47, 859-866 (Pubitemid 28255657)
95. Braz, J. C., Gregory, K., Pathak, A., Zhao, W., Sahin, B., Klevitsky, R., Kimball, T. F., Lorenz, J. N., Nairn, A. C., Liggett, S. B. et al. (2004) PKCa regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248-254
96. Wakasaki, H., Koya, D., Schoen, F. J., Jirousek, M. R., Ways, D. K., Hoit, B. D., Walsh, R. A. and King, G. L. (1997) Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 94, 9320-9325
97. Topham, M. K. and Prescott, S. M. (2002) Diacylglycerol kinases: regulation and signaling roles. Thrombosis Haemostasis 88, 912-918 (Pubitemid 36018775)
98. Harada, M., Takeishi, Y., Arimoto, T., Niizeki, T., Kitahara, T., Goto, K., Walsh, R. A. and Kubota, I. (2007) Diacylglycerol kinase ζ attenuates pressure overload-induced cardiac hypertrophy. Circ. J. 71, 276-282 (Pubitemid 46182705)
99. Bilim, O., Takeishi, Y., Kitahara, T., Arimoto, T., Niizeki, T., Sasaki, T., Goto, K. and Kubota, I. (2008) Diacylglycerol kinase ζ inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Cardiovasc. Diabetol. 7, 2
100. Xia, Z., Kuo, K.-H., Nagareddy, P. R., Wang, F., Guo, Z., Guo, T., Jiang, J. and McNeill, J. H. (2007) N-acetylcysteine attenuates PKCβ2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc. Res. 73, 770-782
101. Hambleton, M., Hahn, H., Pleger, S. T., Kuhn, M. C., Klevitsky, R., Carr, A. N., Kimball, T. F., Hewett, T. E., Dorn, 2nd, G. W., Koch, W. J. and Molkentin, J. D. (2006) Pharmacological- and gene therapy-based inhibition of protein kinase Cα/β enhances cardiac contractility and attenuates heart failure. Circulation 114, 574-582
102. Arikawa, E., Ma, R. C.W., Isshiki, K., Luptak, I., He, Z., Yasuda, Y., Maeno, Y., Patti, M. E., Weir, G. C., Harris, R. A. et al. (2007) Effects of insulin replacements, inhibitors of angiotensin, and PKCβ's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 56, 1410-1420 (Pubitemid 46715615)
103. Montagnani, M. (2008) Diabetic cardiomyopathy: how much does it depend on AGE? Br. J. Pharmacol. 154, 725-726 (Pubitemid 351821582)
104. Aragno, M., Mastrocola, R., Medana, C., Catalano, M. G., Vercellinatto, I., Danni, O. and Boccuzzi, G. (2006) Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 147, 5967-5974 (Pubitemid 44833515)
105. Carley, A. N. and Severson, D. L. (2008) What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice? Cardiovasc. Drugs Ther. 22, 83-89
106. Bers, D. M. (2002) Cardiac excitation-contraction coupling. Nature 415, 198-205 (Pubitemid 34059525)
107. 2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51, 1166-1171
108. 2+ overload. J. Physiol. 527, 85-94
109. 2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55, 608-615
110. + ATPase activities and gene expression in alloxan-induced diabetes in rats. Mol. Cell. Biochem. 188, 91-101
111. 2+ handling in normal and diabetic rat hearts. FASEB J. 16, 1657-1659
112. 2+ release in cardiomyocytes by angiotensin II receptor blockade. Am. J. Physiol. Heart Circ. Physiol. 292, H912-H920
113. Shishehbor, M. H., Hoogwerf, B. J., Schoenhagen, P., Marso, S. P., Sun, J. P., Li, J., Klein, A. L., Thomas, J. D. and Garcia, M. J. (2003) Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. Am. J. Cardiol. 91, 1514-1517
114. Jweied, E. E., McKinney, R. D., Walker, L. A., Brodsky, I., Geha, A. S., Massad, M. G., Buttrick, P. M. and de Tombe, P. P. (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 289, H2478-H2483
115. Qin, D., Huang, B., Deng, L., El-Adawi, H., Ganguly, K., Sowers, J. R. and El-Sherif, N. (2001) Downregulation of K+ channel genes expression in type I diabetic cardiomyopathy. Biochem. Biophys. Res. Commun. 283, 549-553
116. Dostal, D. E., Rothblum, K. N., Chernin, M. I., Cooper, G. R. and Baker, K. M. (1992) Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am. J. Physiol. 263, C838-C850
117. Privratsky, J. R., Wold, L. E., Sowers, J. R., Quinn, M. T. and Ren, J. (2003) AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42, 206-212 (Pubitemid 36944598)
118. Connelly, K. A., Kelly, D. J., Zhang, Y., Prior, D. L., Martin, J., Cox, A. J., Thai, K., Feneley, M. P., Tsoporis, J., White, K. E. et al. (2007) Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc. Res. 76, 280-291
119. Raimondi, L., De Paoli, P., Mannucci, E., Lonardo, G., Sartiani, L., Banchelli, G., Pirisino, R., Mugelli, A. and Cerbai, E. (2004) Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 53, 1927-1933 (Pubitemid 38857056)
120. Fiordaliso, F., Cuccovillo, I., Bianchi, R., Bai, A., Doni, M., Salio, M., De Angelis, N., Ghezzi, P., Latini, R. and Masson, S. (2006) Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci. 79, 121-129 (Pubitemid 43737057)
121. Liu, X., Suzuki, H., Sethi, R., Tappia, P. S., Takeda, N. and Dhalla, N. S. (2006) Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann. N. Y. Acad. Sci. 1084, 141-154
122. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (Pubitemid 30068516)
123. Zannad, F., Alla, F., Dousset, B., Perez, A. and Pitt, B. (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102, 2700-2706 (Pubitemid 30949246)
124. McEwan, P. E., Gray, G. A., Sherry, L., Webb, D. J. and Kenyon, C. J. (1998) Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 98, 2765-2773 (Pubitemid 28564014)
125. Neumann, S., Huse, K., Semrau, R., Diegeler, A., Gebhardt, R., Buniatian, G. H. and Scholz, G. H. (2002) Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39, 756-760 (Pubitemid 34252870)
126. Liu, Y., Cox, S. R., Morita, T. and Kourembanas, S. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77, 638-643
127. Richard, D. E., Berra, E. and Pouyssegur, J. (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J. Biol. Chem. 275, 26765-26771
128. Abaci, A., Oguzhan, A., Kahraman, S., Eryol, N. K., Unal, S., Arinc, H. and Ergin, A. (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99, 2239-2242 (Pubitemid 29201128)
129. Shinohara, K., Shinohara, T., Mochizuki, N., Mochizuki, Y., Sawa, H., Kohya, T., Fujita, M., Fujioka, Y., Kitabatake, A. and Nagashima, K. (1996) Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels 11, 113-122 (Pubitemid 26331571)
130. Chou, E., Suzuma, I., Way, K. J., Opland, D., Clermont, A. C., Naruse, K., Suzuma, K., Bowling, N. L., Vlahos, C. J., Aiello, L. P. and King, G. L. (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105, 373-379 (Pubitemid 34106188)
131. Emoto, M., Anno, T., Sato, Y., Tanabe, K., Okuya, S., Tanizawa, Y., Matsutani, A. and Oka, Y. (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 50, 1166-1170 (Pubitemid 32374549)
132. Ebrahimian, T. G., Heymes, C., You, D., Blanc-Brude, O., Mees, B., Waeckel, L., Duriez, M., Vilar, J., Brandes, R. P., Levy, B. I. et al. (2006) NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am. J. Pathol. 169, 719-728
133. Jesmin, S., Zaedi, S., Shimojo, N., Iemitsu, M., Masuzawa, K., Yamaguchi, N., Mowa, C. N., Maeda, S., Hattori, Y. and Miyauchi, T. (2007) Endothelin
134. Tschope, C., Schultheiss, H. P., Walther, T., Tschope, C., Schultheiss, H.-P. and Walther, T. (2002) Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J. Cardiovasc. Pharmacol. 39, 478-487
135. Tschope, C. and Westermann, D. (2008) Development of diabetic cardiomyopathy and the kallikrein-kinin system-new insights from B1 and B2 receptor signaling. Biol. Chem. 389, 707-711
136. Spillmann, F., Van Linthout, S., Schultheiss, H. P. and Tschöpe, C. (2006) Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Curr. Opin. Nephrol. Hypertension 15, 22-29
137. Cloutier, F. and Couture, R. (2000) Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br. J. Pharmacol. 130, 375-385
138. Tschope, C., Walther, T., Yu, M., Reinecke, A., Koch, M., Seligmann, C., Heringer, S. B., Pesquero, J. B., Bader, M., Schultheiss, H. and Unger, T. (1999) Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology 44, 35-42
139. Pelikanova, T., Pinsker, P., Smrckova, I., Stribrna, L. and Dryakova, M. (1998) Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus. J. Diabetes Compl. 12, 264-272 (Pubitemid 28423397)
140. Rett, K., Wicklmayr, M., Dietze, G. J. and Haring, H. U. (1996) Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 45 (Suppl. 1), S66-S69 (Pubitemid 26011992)
141. Shiuchi, T., Cui, T. X., Wu, L., Nakagami, H., Takeda-Matsubara, Y., Iwai, M. and Horiuchi, M. (2002) ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40, 329-334 (Pubitemid 35006719)
142. Montanari, D., Yin, H., Dobrzynski, E., Agata, J., Yoshida, H., Chao, J. and Chao, L. (2005) Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 54, 1573-1580 (Pubitemid 40586692)
143. Tschope, C., Walther, T., Escher, F., Spillmann, F., Du, J., Altmann, C., Schimke, I., Bader, M., Sanchez-Ferrer, C. F., Schultheiss, H. P. and Noutsias, M. (2005) Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 19, 2057-2059 (Pubitemid 41759764)
144. Mikrut, K., Paluszak, J., Kozlik, J., Sosnowski, P., Krauss, H. and Grzeskowiak, E. (2001) The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res. Clin. Prac. 51, 79-85
145. 2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J. 18, 1967-1969
146. Tschope, C., Walther, T., Koniger, J., Spillmann, F., Westermann, D., Escher, F., Pauschinger, M., Pesquero, J. B., Bader, M., Schultheiss, H. P. and Noutsias, M. (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 18, 828-835 (Pubitemid 38544501)
147. Regan, T. J., Wu, C. F., Yeh, C. K., Oldewurtel, H. A. and Haider, B. (1981) Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ. Res. 49, 1268-1277
148. Haider, B., Yeh, C. K., Thomas, G., Oldewurtel, H. A., Lyons, M. M. and Regan, T. J. (1981) Influence of diabetes on the myocardium and coronary arteries of rhesus monkey fed an atherogenic diet. Circ. Res. 49, 1278-1288
149. Bhimji, S., Godin, D. V. and McNeill, J. H. (1986) Myocardial ultrastructural changes in alloxan-induced diabetes in rabbits. Acta Anat. (Basel) 125, 195-200
150. Giacomelli, F. and Wiener, J. (1979) Primary myocardial disease in the diabetic mouse. An ultrastructural study. Lab. Invest. 40, 460-473
151. Jackson, C. V., McGrath, G. M., Tahiliani, A. G., Vadlamudi, R. V. and McNeill, J. H. (1985) A functional and ultrastructural analysis of experimental diabetic rat myocardium. Manifestation of a cardiomyopathy. Diabetes 34, 876-883
152. Hsiao, Y. C., Suzuki, K., Abe, H. and Toyota, T. (1987) Ultrastructural alterations in cardiac muscle of diabetic BBWistar rats. Virchows Arch. A Pathol. Anat. Histopathol. 411, 45-52
153. Thompson, E.W. (1988) Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. Am. J. Anat. 182, 270-282
154. Tarach, J. S. (1976) Histomorphological and ultrastructural studies of a rat myocardium in experimental conditions. Z Mikrosk Anat. Forsch. 90, 1145-1157
155. Reinila, A. and Akerblom, H. K. (1984) Ultrastructure of heart muscle in short-term diabetic rats: influence of insulin treatment. Diabetologia 27, 397-402 (Pubitemid 14044465)
156. Koltai, M. Z., Balogh, I., Wagner, M. and Pogatsa, G. (1984) Diabetic myocardial alterations in ultrastructure and function. Exp. Pathol. 25, 215-221
157. Fischer, V. W., Barner, H. B. and Larose, L. S. (1984) Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum. Pathol. 15, 1127-1136
158. Dyntar, D., Eppenberger-Eberhardt, M., Maedler, K., Pruschy, M., Eppenberger, H. M., Spinas, G. A. and Donath, M. Y. (2001) Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50, 2105-2113 (Pubitemid 33643679)
159. Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B. and Anversa, P. (2000) Myocardial cell death in human diabetes. Circ. Res. 87, 1123-1132
160. Dyntar, D., Sergeev, P., Klisic, E., Ambuhl, P., Schaub, M. C. and Donath, M. Y. (2006) High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J. Clin. Endocrinol. Metab. 91, 1961-1967
161. Backlund, T., Palojoki, E., Saraste, A., Eriksson, A., Finckenberg, P., Kytö, V., Lakkisto, P., Mervaala, E., Voipio-Pulkki, L. M., Laine, M. and Tikkanen, I. (2004) Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia 47, 325-330 (Pubitemid 38315370)
162. Cai, L. and Kang, Y. J. (2003) Cell death and diabetic cardiomyopathy. Cardiovasc. Toxicol. 3, 219-228
163. Saito, K., Nishi, S., Kashima, T. and Tanaka, H. (1984) Histologic and ultrastructural studies on the myocardium in spontaneously diabetic KK mice: a new animal model of cardiomyopathy. Am. J. Cardiol. 53, 320-323
164. Okruhlicova, L., Tribulova, N., Weismann, P. and Sotnikova, R. (2005) Ultrastructure and histochemistry of rat myocardial capillary endothelial cells in response to diabetes and hypertension. Cell Res. 15, 532-538 (Pubitemid 41653923)
165. Silver, M. D., Huckell, V. F. and Lorber, M. (1977) Basement membranes of small cardiac vessels in patients with diabetes and myxoedema: preliminary observations. Pathology 9, 213-220 (Pubitemid 8182320)
166. Thompson, E.W. (1994) Quantitative analysis of myocardial structure in insulin-dependent diabetes mellitus: effects of immediate and delayed insulin replacement. Proc. Soc. Exp. Biol. Med. 205, 294-305
167. Cameron, D. P., Amherdt, M., Leuenberger, P., Orci, L. and Stauffacher, W. (1973) Microvascular alterations in chronically streptozotocin-diabetic rats. Adv. Metab. Disord. 2 (Suppl. 2), 257-269
168. Kilo, C., Vogler, N. and Williamson, J. R. (1972) Muscle capillary basement membrane changes related to aging and to diabetes mellitus. Diabetes 21, 881-905
169. Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T. and Johnson, J. A. (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28, 2345-2351 (Pubitemid 41384275)
170. Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M. and Krumholz, H. M. (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111, 583-590 (Pubitemid 40216485)
171. Eurich, D. T., McAlister, F. A., Blackburn, D. F., Majumdar, S. R., Tsuyuki, R. T., Varney, J. and Johnson, J. A. (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br. Med. J. 335, 497
172. Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H. and Clase, C. M. (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30, 389-394 (Pubitemid 46198354)
173. Chan, A. Y., Soltys, C. L., Young, M. E., Proud, C. G. and Dyck, J. R. (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 279, 32771-32779
174. McGuire, D. K. and Inzucchi, S. E. (2008) New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 117, 440-449
175. Hallsten, K., Virtanen, K. A., Lonnqvist, F., Janatuinen, T., Turiceanu, M., Rönnemaa, T., Viikari, J., Lehtimäki, T., Knuuti, J. and Nuutila, P. (2004) Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabetes Med. 21, 1280-1287 (Pubitemid 39620050)
176. Giles, T. D., Miller, A. B., Elkayam, U., Bhattacharya, M. and Perez, A. (2008) Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J. Card. Failure 14, 445-452 (Pubitemid 352040859)
177. Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
178. St John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., Patel, J. and Freed, M. (2002) A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25, 2058-2064
179. Lago, R. M., Singh, P. P. and Nesto, R. W. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370, 1129-1136 (Pubitemid 47464583)
180. Lincoff, A. M., Wolski, K., Nicholls, S. J. and Nissen, S. E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, J. Am. Med. Assoc. 298, 1180-1188 (Pubitemid 47403104)
181. Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A.M., Tan, M. H., Lefèbvre, P. J., Murray, G. D. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (Pubitemid 41416583)
182. Betteridge, D. J., DeFronzo, R. A. and Chilton, R. J. (2008) PROactive: time for a critical appraisal. Eur. Heart J. 29, 969-983
183. Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M. and McMurray, J. J. (2007) Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N. Engl. J. Med. 357, 28-38
184. Swedberg, K., Pfeffer, M., Granger, C., Held, P., McMurray, J., Ohlin, G., Olofsson, B., Ostergren, J. and Yusuf, S. (1999) Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J. Card. Failure 5, 276-282
185. Nystrom, T. (2008) The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 40, 593-606
186. Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D. and Shannon, R. P. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (Pubitemid 38282847)
187. Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D. and Shannon, R. P. (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Failure 12, 694-699 (Pubitemid 44881367)
188. Fragasso, G., Palloshi, A., Puccetti, P., Silipigni, C., Rossodivita, A., Pala, M., Calori, G., Alfieri, O. and Margonato, A. (2006) A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 48, 992-998
189. Lee, L., Campbell, R., Scheuermann-Freestone, M., Taylor, R., Gunaruwan, P., Williams, L., Ashrafian, H., Horowitz, J., Fraser, A. G., Clarke, K. and Frenneaux, M. (2005) Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112, 3280-3288 (Pubitemid 43739373)
190. McCormack, J. G., Barr, R. L., Wolff, A. A. and Lopaschuk, G. D. (1996) Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93, 135-142 (Pubitemid 26007542)
191. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., Harrap, S., Poulter, N., Marre, M., Cooper, M. et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (Pubitemid 47362321)
192. Yusuf, S., Teo, K. K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P. and Anderson, C. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559
193. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153
194. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R. and Raz, I. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860
195. Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B. et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and β-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J. Am. Coll. Cardiol. 41, 1529-1538
196. Cohn, J. N. and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675
197. Wlodarczyk, J. H., Keogh, A., Smith, K. and McCosker, C. (2003) CHART: congestive cardiac failure in hospitals, an Australian review of treatment. Heart Lung Circ. 12, 94-102 (Pubitemid 37265886)
198. Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Wright, Jr, J. T., Oakes, R., Lukas, M. A. et al. (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 292, 2227-2236
199. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (Pubitemid 29037695)
200. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B. et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658
201. Nemoto, O., Kawaguchi, M., Yaoita, H., Miyake, K., Maehara, K. and Maruyama, Y. (2006) Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ. J. 70, 327-334 (Pubitemid 43312257)
202. Fredersdorf, S., Thumann, C., Ulucan, C., Griese, D. P., Luchner, A., Riegger, G. A., Kromer, E. P. and Weil, J. (2004) Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc. Pathol. 13, 11-19
203. Poornima, I. G., Parikh, P. and Shannon, R. P. (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605
204. Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O'Donnell, C. P. and Hare, J. M. (2003) Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754-759 (Pubitemid 36999263)
205. Rutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G., Meigs, J. B., Nesto, R. W., Wilson, P. W. and Vasan, R. S. (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107, 448-454 (Pubitemid 36158048)
206. Tenenbaum, A., Fisman, E. Z., Schwammenthal, E., Adler, Y., Benderly, M., Motro, M. and Shemesh, J. (2003) Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus. Cardiovasc. Diabetol. 2, 14
207. Yarom, R., Zirkin, H., Stammler, G. and Rose, A. G. (1992) Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J. Pathol. 166, 265-270
208. Nunoda, S., Genda, A., Sugihara, N., Nakayama, A., Mizuno, S. and Takeda, R. (1985) Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1, 43-47 (Pubitemid 15021712)
209. Kawaguchi, M., Asakura, T., Saito, F., Nemoto, O., Maehara, K., Miyake, K., Sugai, N. and Maruyama, Y. (1999) [Changes in diameter size and F-actin expression in themyocytes of patients with diabetes and streptozotocin-induced diabetes model rats]. J. Cardiol. 34, 333-339